HomeInsightsStock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Zydus Lifesciences Ltd Stock Comparison

Glaxosmithkline Pharmaceuticals Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 3098 as of 22 Jul 15:30.
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 226.4 on March 2020 to 52.5 on March 2025 . This represents a CAGR of -21.62% over 6 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 19.7 on March 2025 . This represents a CAGR of -2.76% over 6 years.
  • The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 21095 crore on March 2020 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.98% over 6 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 89122 crore on March 2025 . This represents a CAGR of 21.76% over 6 years.
  • The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 1015 crore as compare to the Dec '24 revenue of ₹ 984.49 crore. This represent the growth of 3.1% The revenue of Zydus Lifesciences Ltd for the Mar '25 is ₹ 6608 crore as compare to the Dec '24 revenue of ₹ 5326 crore. This represent the growth of 24.07%.
  • The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '25 is ₹ 373.87 crore as compare to the Dec '24 ebitda of ₹ 326.99 crore. This represent the growth of 14.34% The ebitda of Zydus Lifesciences Ltd for the Mar '25 is ₹ 1986 crore as compare to the Dec '24 ebitda of ₹ 1444 crore. This represent the growth of 37.49%.
  • The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 132.25 crore to ₹ 262.87 crore over 8 quarters. This represents a CAGR of 40.98% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1248 crore over 8 quarters. This represents a CAGR of 5.97% .
  • The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 615.76 % on March 2020 to 99.54 % on March 2025 . This represents a CAGR of -26.19% over 6 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 19.16 % on March 2025 . This represents a CAGR of -4.57% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
  • The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

GlaxoSmithKline Pharmaceuticals declare Quarterly Result

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

27 Jun 2025 11:08

News

GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same per...

Read more

14 May 2025 12:47

News

GlaxoSmithKline Pharmaceuticals AGM scheduled

GlaxoSmithKline Pharmaceuticals announced that the Annual General Meeting(AGM) of the comp...

Read more

13 May 2025 17:18

News

Board of GlaxoSmithKline Pharmaceuticals recommends final dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

13 May 2025 17:18

News

GlaxoSmithKline Pharmaceuticals to conduct board meeting

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

19 Apr 2025 09:56

News

Glaxosmithkline Pharmaceuticals Ltd leads gainers in 'A' group

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmala...

Read more

06 Feb 2025 12:00

Zydus Lifesciences Ltd News Hub

News

Zydus' Matoda facility completes Remote Regulatory Assessment of USFDA

Zydus Lifesciences announced that the USFDA conducted a Remote Regulatory Assessment (RRA)...

Read more

16 Jul 2025 17:55

News

Zydus Lifesciences gets USFDA Nod for Celecoxib Capsules

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones ...

Read more

15 Jul 2025 15:45

News

Zydus Life Matoda facility receives two observations from USFDA after inspection

In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspect...

Read more

19 Jun 2025 09:50

News

Zydus Lifesciences appoints Managing Director

Zydus Lifesciences has approved the appointment of s. Swati Dalal as the Additional Direct...

Read more

16 Jun 2025 14:16

News

Zydus Life subsidiary ZHL appoints Swati Dalal as MD

The appointment was approved by the nomination and remuneration committee (NRC). Swati Dal...

Read more

16 Jun 2025 14:42

News

Zydus Life receives USFDA EIR for Gujarat facility

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the r...

Read more

12 Jun 2025 09:55

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Zydus Lifesciences Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 52,808 Cr while Market cap of Zydus Lifesciences Ltd is 97,579 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Zydus Lifesciences Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Zydus Lifesciences Ltd?

As of July 22, 2025, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹3117.3. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹969.75.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions